Chauncey Perry Colwell “Skip” Dickson, Jr. 89 of Millbrook, NY passed on October 7, 2025 after a disastrous fall on August 12, 2025 that left him paralyzed. Born in Poughkeepsie, NY on May 9, 1936 to ...

TUALATIN — As the Portland Trail Blazers sauntered away from the practice court Tuesday afternoon and prepared for a flight to San Francisco, coach Chauncey Billups had a lot to think over. What would ...

Heroes get remembered, but legends never die. “The Sandlot” star Chauncey Leopardi, 44, has opened up about why he slowly stepped back from Hollywood following a slew of successful roles in the 90s ...

Safety C.J. Gardner-Johnson, who was released last month after just three games with the Houston Texans, has landed a practice squad deal with the Baltimore Ravens, per ESPN's Adam Schefter.

Dr Reddy's Labs falls 6% after firm gets non-compliance notice for semaglutide in Canada Oct 30 2025 11:10 AM Stocks to Watch Today: Wipro, Dr Reddys Labs, CONCOR, Dilip Buildcon, SAIL, Sagility India ...

Mahamudu Bawumia (born October 7, 1963) is an economist and banker.He was a Deputy Governor of the Bank of Ghana until his nomination as Vice Presidential candidate for the New Patriotic Party (NPP) ...

Camila Araujo removed her OnlyFans link from her social media bios ahead of releasing her podcast episode with McKinley Richardson, saying she did not want to profit from someone else's trauma. The ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

The New York Giants will be especially shorthanded on Sunday against the Denver Broncos, downgrading several players, including wide receiver Darius Slayton, to "out." On Friday, the Giants release ...

Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.